2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | MOLECULAR CANCER THERAPEUTICS MOL CANCER THER LetPub评分 7.9
51人评分
我要评分
声誉 8.8 影响力 6.7 速度 9.6 | |||||||||||||||||||||
| 期刊ISSN | 1535-7163 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1538-8514 | |||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 6.009 点击查看影响因子趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 1.40%点击查看自引率趋势图 | |||||||||||||||||||||
| h-index | 157 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication. | |||||||||||||||||||||
| 期刊官方网站 | http://mct.aacrjournals.org/ | |||||||||||||||||||||
| 期刊投稿网址 | http://mct.msubmit.net/cgi-bin/main.plex | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足MOLECULAR CANCER THERAPEUTICS的语言要求，还能让MOLECULAR CANCER THERAPEUTICS编辑和审稿人得到更好的审稿体验，让稿件最大限度地被MOLECULAR CANCER THERAPEUTICS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | |||||||||||||||||||||
| 出版商 | American Association for Cancer Research Inc. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 2001 | |||||||||||||||||||||
| 年文章数 | 230点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 2.94% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 93.04% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：2区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1535-7163%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均3月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约50% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在MOLECULAR CANCER THERAPEUTICS顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Breast Cancer Author: Peng, Peng; Qiang, Xiaoyan; Li, Guoyu; Li, Lin; Ni, Shumao; Yu, Qi; Sourd, Laura; Marangoni, Elisabetta; Hu, Chao; Wang, Dong; Wu, Di; Wu, Frank Journal: MOLECULAR CANCER THERAPEUTICS. 2023; Vol. 22, Issue 2, pp. 205-214. DOI: 10.1158/1535-7163.MCT-22-0012 PubMed DOI |
| 2. | Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer Author: Li, Chengxun; Zhang, Jiale; Wu, Qiming; Kumar, Anuj; Pan, Guihong; Kelvin, David J. Journal: MOLECULAR CANCER THERAPEUTICS. 2023; Vol. 22, Issue 3, pp. 306-316. DOI: 10.1158/1535-7163.MCT-22-0159 PubMed DOI |
| 3. | Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS Author: Wang, Xing; Raman, Natasha; Lemtiri-Chlieh, Ghali; Chang, Jinhee; Jagtap, Shreya; Chowdhury, Dipanwita Dutta; Ballew, Matthew; Carrieri, Francesca Anna; Nguyen, Triet; Nugent, Katriana; Peck, Travis; Levine, Michelle S.; Chan, Aaron; Lam, Christine; Malek, Reem; Hoang, Tung; Phillips, Ryan; Cheng, ZhuoAn; Taparra, Kekoa; Connis, Nick; Hann, Christine L.; Holland, Andrew; Tran, Phuoc T.; Lafargue, Audrey; Wang, Hailun Journal: MOLECULAR CANCER THERAPEUTICS. 2023; Vol. 22, Issue 4, pp. 519-528. DOI: 10.1158/1535-7163.MCT-22-0191 PubMed DOI |
| 4. | Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-KB-Triggered SASP in Cancer-Associated Fibroblasts Author: Jin, Ping; Li, Xin; Xia, Yu; Li, Huayi; Li, Xiaoting; Yang, Zong-Yuan; Wang, Zhen; Xu, Cheng; Fang, Tian; Zhou, Dongchen; Xiong, Xiaoming; Wang, Si-Yuan; Xu, Sen; Gao, Qinglei Journal: MOLECULAR CANCER THERAPEUTICS. 2023; Vol. 22, Issue 4, pp. 447-458. DOI: 10.1158/1535-7163.MCT-22-0396 PubMed DOI |
| 5. | Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. Author: Feng J, Zhang S, Wu K, Wang B, Wong JY, Jiang H, Xu R, Ying L, Huang H, Zheng X, Chen X, Ma S. Journal: Mol Cancer Ther. 2016 May;15(5):842-53. doi: 10.1158/1535-7163.MCT-15-0445. Epub 2016 Feb 2. PubMed |
| 6. | Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption. Author: Xu L, Luo J, Jin R, Yue Z, Sun P, Yang Z, Yang X, Wan W, Zhang J, Li S, Liu M, Xiao J. Journal: Mol Cancer Ther. 2016 May;15(5):854-65. doi: 10.1158/1535-7163.MCT-15-0669. Epub 2016 Feb 9. PubMed |
| 7. | Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Author: Karan G, Wang H, Chakrabarti A, Karan S, Liu Z, Xia Z, Gundluru M, Moreton S, Saunthararajah Y, Jackson MW, Agarwal MK, Wald DN. Journal: Mol Cancer Ther. 2016 Apr;15(4):574-82. doi: 10.1158/1535-7163.MCT-15-0467. Epub 2016 Feb 16. PubMed |
| 8. | Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression. Author: Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD, Wang ZX. Journal: Mol Cancer Ther. 2016 May;15(5):1082-94. doi: 10.1158/1535-7163.MCT-15-0707. Epub 2016 Feb 23. PubMed |
| 9. | Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis. Author: Yang J, Qian S, Cai X, Lu W, Hu C, Sun X, Yang Y, Yu Q, Gao SP, Cao P. Journal: Mol Cancer Ther. 2016 Jun;15(6):1190-200. doi: 10.1158/1535-7163.MCT-15-0551. Epub 2016 Feb 29. PubMed |
| 10. | Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Author: Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR, Hill R. Journal: Mol Cancer Ther. 2016 May;15(5):1043-52. doi: 10.1158/1535-7163.MCT-15-0774. Epub 2016 Mar 3. PubMed |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共4条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
